Veru’s (VERU) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Veru (NASDAQ:VERU) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Veru Stock Down 1.3 %

Shares of Veru stock opened at $0.73 on Tuesday. The company has a market capitalization of $107.37 million, a PE ratio of -1.53 and a beta of -0.47. Veru has a 52 week low of $0.36 and a 52 week high of $1.92. The stock’s fifty day moving average is $0.82 and its two-hundred day moving average is $0.95.

Veru (NASDAQ:VERU) last posted its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. The company had revenue of $3.95 million during the quarter, compared to analysts’ expectations of $3.50 million. During the same quarter last year, the firm earned ($0.13) EPS. As a group, research analysts anticipate that Veru will post -0.3 earnings per share for the current year.

Institutional Trading of Veru

Several hedge funds and other institutional investors have recently made changes to their positions in VERU. Cetera Advisors LLC purchased a new position in Veru during the 1st quarter worth $33,000. Gladstone Institutional Advisory LLC grew its stake in shares of Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock worth $44,000 after acquiring an additional 14,500 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Veru by 185.9% during the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock valued at $51,000 after acquiring an additional 42,997 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Veru by 3,994.8% during the second quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock valued at $96,000 after acquiring an additional 110,857 shares in the last quarter. Finally, SeaCrest Wealth Management LLC boosted its stake in Veru by 313.8% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 120,000 shares of the company’s stock worth $101,000 after purchasing an additional 91,000 shares in the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.